Re: How much is life worth: cetuximab, non-small cell lung cancer, and the $440 billion question.
Cohen
Joshua
J
Looney
William
W
D000911:Antibodies, Monoclonal / Q000191:economics* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000191:economics* / Q000627:therapeutic use; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy / Q000191:economics*; D000068818:Cetuximab; D003362:Cost-Benefit Analysis; D016527:Drug Costs; D019317:Evidence-Based Medicine; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy / Q000191:economics*; D056687:Off-Label Use / Q000706:statistics & numerical data; D019057:Quality-Adjusted Life Years; D012051:Reimbursement Mechanisms; D014481:United States
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000068818:Cetuximab